The Relationship Between rs3212986C>A Polymorphism and Tumor Stage in Lung Cancer Patients.
clinicopathological features
ercc1
nsclc
sequencing
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
10 Apr 2019
10 Apr 2019
Historique:
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
28
6
2019
Statut:
epublish
Résumé
Background The nucleotide excision repair (NER) system is one of the most important deoxyribonucleic acid (DNA) repair mechanisms and is critical for chemotherapy resistance. We conducted the present study to investigate the association between two polymorphisms of excision of repair cross-complementing group 1 (ERCC1), the key component of the NER pathway, and the clinicopathological features of patients with non-small cell lung cancer (NSCLC). Methods A total of 38 patients with confirmed NSCLC were included in our study. DNA was extracted from peripheral blood. ERCC1 rs3212986 (8092) and rs11615 (118) were genotyped using molecular assays including polymerase chain reaction (PCR) with restriction fragment length polymorphism (by MboII and HpyCH4 enzymes) and sequencing. Results The PCR results indicated the correct performance of the genomics extraction and molecular protocols. The distribution of C/C, C/A and A/A genotypes at position 8092 was 42.10%, 47.36%, and 10.52% respectively (P=0.03). Multivariate regression analysis showed that there was a significant correlation between C8092A (rs3212986) polymorphism and metastasis, grade of the tumor, and response to treatment. Individuals carrying the rs3212986 CA genotype and A allele had a significantly worse response to the treatment. Also, the correlation between alteration at this genomics location and patients with NSCLC who used to smoke cigarettes was positive. However, no significant association was detected between rs11615 C118>T polymorphism and demographic characteristics of patients with NSCLC. Conclusion We concluded that in lung cancer patients there is a relationship between tumor stage and rs3212986C>A polymorphism.
Identifiants
pubmed: 31245210
doi: 10.7759/cureus.4423
pmc: PMC6559387
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e4423Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):843-7
pubmed: 10952103
Int J Cancer. 2001 May 15;92(4):562-7
pubmed: 11304692
Clin Cancer Res. 2004 Aug 1;10(15):4939-43
pubmed: 15297394
Cancer Res. 2004 Oct 1;64(19):6863-6
pubmed: 15466174
Reprod Biomed Online. 2008 Jul;17(1):36-41
pubmed: 18616887
Lung Cancer. 2009 May;64(2):131-9
pubmed: 18804893
Clin Cancer Res. 2009 Apr 1;15(7):2281-90
pubmed: 19318487
Genome Med. 2010 Dec 23;2(12):92
pubmed: 21205279
Mutagenesis. 2012 Jan;27(1):67-76
pubmed: 22002622
J Cancer Res Clin Oncol. 2012 Feb;138(2):311-6
pubmed: 22127368
BMJ Open. 2013 Jan 03;3(1):null
pubmed: 23293248
Mol Cell Biochem. 2013 May;377(1-2):45-53
pubmed: 23435956
PLoS One. 2013 Jul 02;8(7):e66157
pubmed: 23843950
Value Health. 2013 Sep-Oct;16(6 Suppl):S4-9
pubmed: 24034312
Oncol Lett. 2013 Sep;6(3):648-654
pubmed: 24137384
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18946-51
pubmed: 24158479
Sci Rep. 2014 Feb 17;4:4112
pubmed: 24531312
Iran Red Crescent Med J. 2014 Jul;16(7):e16659
pubmed: 25237569
J Thorac Dis. 2014 Oct;6(Suppl 5):S589-96
pubmed: 25349710
Genet Mol Res. 2014 Oct 27;13(4):8722-8
pubmed: 25366763
Mutagenesis. 2015 May;30(3):441-9
pubmed: 25690281
Genet Mol Res. 2016 May 23;15(2):
pubmed: 27323074
Open Access Maced J Med Sci. 2018 Dec 14;6(12):2277-2282
pubmed: 30607176
Oncol Lett. 2019 May;17(5):4068-4084
pubmed: 30944600
Am J Hypertens. 1997 Sep;10(9 Pt 1):1064-8
pubmed: 9324115